Dupilumab improves patient-reported sleep quality in patients with severe, uncontrolled CRSwNP
A systematic review of 7 studies (n=2164) found that dupilumab consistently improved sleep quality outcomes in CRSwNP patients, including SNOT-22 sleep domain (mean reduction up to -7.02 points at 24 weeks, p<0.001), PSQI, ESS, and ISI scores. One study reported a decrease in poor global sleep quality from 88.9% at baseline to 5.7% at 12 months. However, evidence is limited by lack of objective sleep measures and high risk of bias in observational studies.
This article is automatically generated from the structured evidence profile behind the claim above. Scores reflect the quality and quantity of available research, not clinical advice.
Dupilumab improves patient-reported sleep quality in patients with severe, uncontrolled CRSwNP The current body of evidence comprises 1 study and 1 meta-analysis. EvidenceHub rates the overall confidence at 49/100 (low).
The Claim
Dupilumab improves patient-reported sleep quality in patients with severe, uncontrolled CRSwNP
This conclusion is most relevant to: Adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).
What the Research Shows
The conclusion draws on 1 linked study. Highlights from the cited literature:
- ▸Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review. (Journal of clinical medicine, 2026) —
How It Works
The proposed biological pathway:
- ▸Dupilumab blocks IL-4 receptor alpha, inhibiting IL-4 and IL-13 signaling
- ▸Reduces type 2 inflammation in nasal polyps and sinonasal mucosa
- ▸Decreases nasal obstruction and other sinonasal symptoms
- ▸May directly improve sleep architecture by reducing cytokine-mediated disruption
- ▸Result: Improved patient-reported sleep quality
Who Might Benefit
Evidence fit by population:
- ▸Adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP)
Recommended Dose
300 mg every 15 days
Limitations & Caveats
Important context when interpreting this evidence:
- ▸No polysomnographic data reported; only patient-reported outcomes
- ▸Most observational studies had serious risk of bias due to unaddressed confounding and lack of blinding
- ▸Lack of comparative head-to-head data with other treatments
Frequently Asked Questions
How does dupilumab improve sleep quality in CRSwNP patients?▼
Dupilumab blocks IL-4/IL-13 signaling, reducing type 2 inflammation and nasal obstruction, which may also directly improve sleep architecture. The review found significant improvements in patient-reported sleep measures.
What sleep outcomes were measured in the studies?▼
The studies used validated tools including the SNOT-22 sleep domain, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI).
What is the recommended dose of dupilumab for CRSwNP?▼
The studies included patients receiving dupilumab 300 mg every 15 days for at least one month, which is the approved dose for severe CRSwNP.
Are there any objective sleep measurements in this review?▼
No, the review found no polysomnographic data. All sleep outcomes were patient-reported, which is a limitation of the evidence.
References
- 1.Moffa A, De Corso E, Nardelli D, Bahgat AY, Loperfido A, Afifi IA, Olszewska E, Baptista PM, Galli J, Casale M. “Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review..” Journal of clinical medicine, 2026. PMID: 42590112 DOI: 10.3390/jcm15156010